WILMINGTON, Mass.--(BUSINESS WIRE)--CardioTech International, Inc. (AMEX: CTE), a developer and manufacturer of advanced medical devices and materials for the treatment of a broad range of disease states, today announced that it has received the necessary Ministry of Health approval to add a 4mm graft for the clinical trial of CardioPass™ , the Company’s proprietary synthetic coronary bypass graft. Until now, the trial was only approved for a 5mm graft.
